📣 VC round data is live. Check it out!

Jasper Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Jasper Therapeutics and similar public comparables like Marinomed Biotech, Celularity, Marker Therapeutics, Barinthus Biotherapeutics and more.

Jasper Therapeutics Overview

About Jasper Therapeutics

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.


Founded

2019

HQ

United States

Employees

64

Financials (LTM)

Revenue:
EBITDA: ($81M)

EV

$142K

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Jasper Therapeutics Financials

Jasper Therapeutics reported last 12-month revenue of — and negative EBITDA of ($81M).

In the same LTM period, Jasper Therapeutics generated — in gross profit, ($81M) in EBITDA losses, and had net loss of ($74M).

Revenue (LTM)


Jasper Therapeutics P&L

In the most recent fiscal year, Jasper Therapeutics reported revenue of and EBITDA of ($83M).

Jasper Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of — and net margin of —.

See analyst estimates for Jasper Therapeutics
LTMLast FY202320242025202620272028
EBITDA($81M)($83M)($68M)($75M)($83M)
Net Profit($74M)($76M)($64M)($71M)($76M)

Financial data powered by Morningstar, Inc.

Jasper Therapeutics Stock Performance

Jasper Therapeutics has current market cap of $28M, and enterprise value of $142K.

Market Cap Evolution


Jasper Therapeutics' stock price is $0.99.

Jasper Therapeutics share price increased by 6.1% in the last 30 days, and decreased by 82.1% in the last year.

Jasper Therapeutics has an EPS (earnings per share) of $-2.71.

See more trading valuation data for Jasper Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$142K$28M6.0%6.1%-28.6%-82.1%$-2.71

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Jasper Therapeutics Valuation Multiples

Jasper Therapeutics trades at (0.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for Jasper Therapeutics

EV / Revenue (LTM)


Jasper Therapeutics Financial Valuation Multiples

As of May 5, 2026, Jasper Therapeutics has market cap of $28M and EV of $142K.

Jasper Therapeutics has a P/E ratio of (0.4x).

LTMLast FY202320242025202620272028
EV/EBITDA(0.0x)(0.0x)(0.0x)(0.0x)(0.0x)
EV/EBIT(0.0x)(0.0x)(0.0x)(0.0x)(0.0x)
P/E(0.4x)(0.4x)(0.4x)(0.4x)(0.4x)
EV/FCF(0.0x)(0.0x)(0.0x)(0.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Jasper Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Jasper Therapeutics Margins & Growth Rates

See estimated margins and future growth rates for Jasper Therapeutics

Jasper Therapeutics Growth Rates

23/2424/2526/2727/2828/29
EBITDA Growth10%11%
EBIT Growth11%10%
Net Profit Growth11%6%
FCF Growth21%22%

Data powered by FactSet, Inc. and Morningstar, Inc.

Jasper Therapeutics Operational KPIs

Jasper Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.3M for the same period.

Access forward-looking KPIs for Jasper Therapeutics
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$1.3M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Jasper Therapeutics Competitors

Jasper Therapeutics competitors include Marinomed Biotech, Celularity, Marker Therapeutics, Barinthus Biotherapeutics, Tevogen Bio, Lantern Pharma, Longeveron, Tempest Therapeutics, SoftOx Solutions and Quantum BioPharma.

Most Jasper Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Marinomed Biotech6.8x4.0x(4.5x)2.1x
Celularity2.4x(0.8x)
Marker Therapeutics3.1x(0.8x)(0.7x)
Barinthus Biotherapeutics0.5x
Tevogen Bio(1.8x)
Lantern Pharma(0.8x)
Longeveron17.7x19.3x(1.0x)
Tempest Therapeutics(1.2x)(1.3x)

This data is available for Pro users. Sign up to see all Jasper Therapeutics competitors and their valuation data.

Start Free Trial

Jasper Therapeutics Funding History

Before going public, Jasper Therapeutics raised $49M in total equity funding, across 2 rounds.


Jasper Therapeutics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jan-20Series AAbingworth; Citadel; Qiming Venture Partners USA; Roche Venture Fund; TSVC$14MJasper Therapeutics raised $14 million in a Series A funding round in January 2020 led by Roche Venture Fund with participation from Abingworth, Citadel, Qiming Venture Partners USA, and TSVC. The company focuses on developing mast cell therapeutics, including product candidates using the monoclonal antibody briquilimab under exclusive licenses from Amgen and Stanford for stem cell clearance prior to hematopoietic stem cell transplantation.
Dec-19Series AAbingworth; Alexandria Venture Investments; Qiming Venture Partners USA; Surveyor Capital$35MJasper Therapeutics, a biotechnology company, launched in December 2019 with a $35 million Series A financing round led by Abingworth LLP and Qiming Venture Partners USA, with participation from Surveyor Capital (a Citadel company) and Alexandria Venture Investments. The funding supports the clinical development of JSP191 (formerly AMG 191), a conditioning antibody designed to clear hematopoietic stem cells from bone marrow, reducing the toxicity of chemotherapy and radiation in preparation for stem cell transplants and gene therapies. Amgen licensed worldwide rights to JSP191 to Jasper as part of the financing, including translational science and materials from Stanford University. JSP191 is in Phase 1 testing as a conditioning agent for somatic cell transplantation in patients with severe combined immunodeficiency (SCID) who had prior failed transplants. The program receives additional support from a $23 million grant commitment by the California Institute for Regenerative Medicine (CIRM). Co-founded by Stanford experts Susan Prohaska, Ph.D., an immunologist and stem cell biologist, and Judith Shizuru, M.D., Ph.D., a hematopoietic stem cell transplant specialist, the company aims to expand curative transplant applications. Jasper's executive team includes biotech veterans like William Lis as Executive Chairman and Interim CEO, with experience in commercial launches and financings. The company focuses on immune modulation, graft engineering, and cell/gene therapies, positioning JSP191 as a foundational asset.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Jasper Therapeutics

When was Jasper Therapeutics founded?Jasper Therapeutics was founded in 2019.
Where is Jasper Therapeutics headquartered?Jasper Therapeutics is headquartered in United States.
How many employees does Jasper Therapeutics have?As of today, Jasper Therapeutics has over 64 employees.
Who is the CEO of Jasper Therapeutics?Jasper Therapeutics' CEO is Jeet Mahal.
Is Jasper Therapeutics publicly listed?Yes, Jasper Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of Jasper Therapeutics?Jasper Therapeutics trades under JSPR ticker.
When did Jasper Therapeutics go public?Jasper Therapeutics went public in 2021.
Who are competitors of Jasper Therapeutics?Jasper Therapeutics main competitors include Marinomed Biotech, Celularity, Marker Therapeutics, Barinthus Biotherapeutics, Tevogen Bio, Lantern Pharma, Longeveron, Tempest Therapeutics, SoftOx Solutions, Quantum BioPharma.
What is the current market cap of Jasper Therapeutics?Jasper Therapeutics' current market cap is $28M.
Is Jasper Therapeutics profitable?No, Jasper Therapeutics is not profitable.
What is the current EBITDA of Jasper Therapeutics?Jasper Therapeutics has negative EBITDA and is not profitable.
What is the current EV/EBITDA multiple of Jasper Therapeutics?Current EBITDA multiple of Jasper Therapeutics is (0.0x).
How many companies Jasper Therapeutics has acquired to date?Jasper Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Jasper Therapeutics has invested to date?Jasper Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Jasper Therapeutics

Lists including Jasper Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial